- Home
- MTCH vs EXEL Comparison
MTCH vs EXEL Comparison
Compare MTCH & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTCH
- EXEL
- Stock Information
- Founded
- MTCH 1986
- EXEL 1994
- Country
- MTCH United States
- EXEL United States
- Employees
- MTCH N/A
- EXEL N/A
- Industry
- MTCH Computer Software: Programming Data Processing
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTCH Technology
- EXEL Health Care
- Exchange
- MTCH Nasdaq
- EXEL Nasdaq
- Market Cap
- MTCH 7.2B
- EXEL 9.8B
- IPO Year
- MTCH 2015
- EXEL 2000
- Fundamental
- Price
- MTCH $27.47
- EXEL $36.50
- Analyst Decision
- MTCH Buy
- EXEL Buy
- Analyst Count
- MTCH 19
- EXEL 18
- Target Price
- MTCH $36.47
- EXEL $37.59
- AVG Volume (30 Days)
- MTCH 4.1M
- EXEL 2.3M
- Earning Date
- MTCH 05-08-2025
- EXEL 05-13-2025
- Dividend Yield
- MTCH 1.38%
- EXEL N/A
- EPS Growth
- MTCH N/A
- EXEL 170.77
- EPS
- MTCH 2.02
- EXEL 1.76
- Revenue
- MTCH $3,450,904,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- MTCH $1.02
- EXEL $5.78
- Revenue Next Year
- MTCH $5.06
- EXEL $10.94
- P/E Ratio
- MTCH $13.57
- EXEL $20.74
- Revenue Growth
- MTCH 0.40
- EXEL 18.50
- 52 Week Low
- MTCH $26.39
- EXEL $20.14
- 52 Week High
- MTCH $38.84
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- MTCH 35.70
- EXEL 45.67
- Support Level
- MTCH $29.76
- EXEL $35.34
- Resistance Level
- MTCH $31.08
- EXEL $40.26
- Average True Range (ATR)
- MTCH 0.90
- EXEL 1.21
- MACD
- MTCH -0.02
- EXEL -0.09
- Stochastic Oscillator
- MTCH 3.22
- EXEL 29.79
About MTCH Match Group Inc.
Match Group Inc is a provider of online dating products. The company's portfolio of brands includes Tinder, Hinge, Match, Meetic, OkCupid, Pairs, Plenty Of Fish, Azar, BLK, and more, each built to increase its user's likelihood of connecting with others. The company has four operating segments: Tinder, Hinge, Evergreen and Emerging, and Match Group Asia. The company generates the majority of its revenue from the Tinder segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.